Pre-eclampsia part 2: prediction, prevention and management
- 8 July 2014
- journal article
- review article
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 10 (9) , 531-540
Abstract
Combinations of biomarkers perform better than single biomarkers for predicting pre-eclampsia, but require external validation before they can be used routinely Potentially effective interventions to prevent pre-eclampsia in patients at risk include early administration of low-dose aspirin or L-arginine in combination with oral antioxidants (vitamins C and E) Maternal plasma levels of angiogenic and antiangiogenic factors identify most patients who will develop early pre-eclampsia, correlate with disease severity and have prognostic value for maternal and/or perinatal complications Management of pre-eclampsia includes control of hypertension, prevention of seizures and timely delivery; steroids are administered to enhance fetal lung maturity if induction of labour before 34 weeks is contemplated In pre-eclampsia at ≥37 weeks of gestation, delivery effectively optimizes pregnancy outcomes; for preterm gestations, the risk of continued pregnancy must be balanced against that of premature birth Women with pre-eclampsia are at increased risk of developing cardiovascular disease, including chronic hypertension, stroke, coronary artery disease, diabetes and end-stage renal disease later in lifeKeywords
This publication has 139 references indexed in Scilit:
- Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysisAmerican Journal of Obstetrics and Gynecology, 2011
- Placental volume and vascular flow assessed by 3D power Doppler and adverse pregnancy outcomesPlacenta, 2011
- Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse modelProceedings of the National Academy of Sciences, 2010
- Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeksAmerican Journal of Obstetrics and Gynecology, 2010
- Magnesium sulphate and other anticonvulsants for women with pre-eclampsiaCochrane Database of Systematic Reviews, 2010
- Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trialThe Lancet, 2009
- Prenatal Screening for AneuploidyNew England Journal of Medicine, 2009
- First-trimester maternal serum PP13 in the risk assessment for preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2008
- Antiplatelet agents for preventing pre-eclampsia and its complicationsCochrane Database of Systematic Reviews, 2007
- Magnesium sulphate and other anticonvulsants for women with pre-eclampsia2003